$DBVT

DBV Technologies S.A.

CIK:0001613780|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Statement of Comprehensive Income [Abstract]
Operating income	$ 0.7	$ 1.5	$ 1.6	$ 2.2
Operating expenses
Research and development expenses	(31.2)	(33.7)	(64.6)	(55.2)
Sales and marketing expenses	(5.5)	(0.4)	(10.4)	(0.7)
General and administrative expenses	(14.6)	(8.5)	(25.1)	(14.1)
Total Operating expenses	(51.3)	(42.6)	(100.1)	(69.9)
Loss from operations	(50.6)	(41.1)	(98.5)	(67.7)
Financial income (expense)	0.4	(0.6)	0.9	(1.1)
Loss before taxes	(50.2)	(41.8)	(97.6)	(68.8)
Income tax	(0.2)	(0.1)	(0.4)	(0.1)
Net loss	(50.4)	(41.9)	(98.0)	(69.0)
Foreign currency translation differences, net of taxes	(0.9)	7.2	(5.3)	7.9
Actuarial gains on employee benefits, net of taxes	0.0	(0.2)	0.0	0.0
Comprehensive loss	$ (51.2)	$ (34.8)	$ (103.3)	$ (61.1)
Basic net loss per share attributable to shareholders (in dollars per share)	$ (0.12)	$ (0.31)	$ (0.23)	$ (0.58)
Diluted net loss per share attributable to shareholders (in dollars per share)	$ (0.12)	$ (0.31)	$ (0.23)	$ (0.58)
Weighted average shares outstanding used in computing per share amounts, basic (in shares)	433,535,486	134,476,503	424,587,737	118,545,638
Weighted average shares outstanding used in computing per share amounts, diluted (in shares)	433,535,486	134,476,503	424,587,737	118,545,638

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Statement of Cash Flows [Abstract]
Net loss for the period	$ (98.0)	$ (69.0)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, amortization and accrued contingencies	1.5	1.7
Expenses related to share-based payments	6.0	2.9
Inventory write-downs	5.6	10.3
Other	0.1	1.0
Changes in operating assets and liabilities:
Decrease (increase) in inventories and work in progress	(5.6)	(10.3)
Decrease (increase) in other current assets	(9.0)	(4.0)
(Decrease) increase in trade payables	(0.4)	14.9
(Decrease) increase in other current and non-current liabilities	(1.6)	(1.5)
Change in operating lease liabilities and right of use assets	(0.1)	0.3
Net cash flow used in operating activities	(101.7)	(53.6)
Cash flows used in investing activities :
Change in property, plant, and equipment	(0.8)	0.0
Change in Other non-current assets	(0.1)	(0.4)
Net cash flows used in investing activities	(0.9)	(0.4)
Cash flows provided by financing activities :
Treasury shares	0.0	0.1
Issuance from Net Capital increase and Share warrants	89.0	116.9
Net cash flows provided by financing activities	89.0	117.0
Effect of exchange rate changes on cash and cash equivalents	(5.6)	7.7
Net (decrease) / increase in cash and cash equivalents	(19.2)	70.8
Net Cash and cash equivalents at the beginning of the period	194.2	32.5
Net cash and cash equivalents at the end of the period	$ 174.9	$ 103.2

Condensed Consolidated Statements of Financial Position (unaudited)	Jun. 30, 2026 USD ($)	Dec. 31, 2025 USD ($)
Current assets :
Cash and cash equivalents	$ 174,900,000	$ 194,200,000
Other current assets	27,000,000.0	18,800,000
Total current assets	201,900,000	212,900,000
Non-current assets
Property, plant, and equipment, net	9,700,000	10,400,000
Right-of-use assets	5,900,000	4,600,000
Other non-current assets	5,800,000	5,800,000
Total non-current assets	21,300,000	20,800,000
Total Assets	223,200,000	233,700,000
Current liabilities:
Trade payables	39,400,000	40,900,000
Short-term operating leases' liabilities	800,000	1,100,000
Current contingencies & Employee Benefits	400,000	200,000
Other current liabilities	13,800,000	15,800,000
Total current liabilities	54,300,000	58,000,000.0
Non-current liabilities
Long-term operating leases' liabilities	6,900,000	5,400,000
Non-current contingencies & Employee Benefits	1,600,000	1,500,000
Total non-current liabilities	8,500,000	6,900,000
Total Liabilities	62,800,000	64,900,000
Shareholders’ equity :
Ordinary shares, €0.10 par value; 296,061,497 and 235,670,864 shares authorized, and issued as of June 30, 2026 and December 31, 2025, respectively,	33,961,702	26,911,786
Additional paid-in capital	408,300,000	541,300,000
Treasury stock, 146,321 and 74,680 ordinary shares as of June 30, 2026 and December 31, 2025, respectively, at cost	(800,000)	(800,000)
Accumulated deficit	(270,300,000)	(393,100,000)
Accumulated other comprehensive income	500,000	500,000
Accumulated currency translation effect	(11,200,000)	(5,900,000)
Total Shareholders’ equity	160,400,000	168,800,000
Total Liabilities and Shareholder's equity	$ 223,200,000	$ 233,700,000